



HAL
open science

Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study.

Amandine Dugard, Bruno Giraudeau, Clarisse Dibao-Dina

► To cite this version:

Amandine Dugard, Bruno Giraudeau, Clarisse Dibao-Dina. Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study.. *BMJ Open*, 2024, 14 (4), pp.e077582. <10.1136/bmjopen-2023-077582>. <hal-04674152>

HAL Id: hal-04674152

<https://hal.science/hal-04674152v1>

Submitted on 21 Aug 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

BMJ Open Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study

Amandine Dugard ¹, Bruno Giraudeau,^{1,2} Clarisse Dibao-Dina ^{1,3}

To cite: Dugard A, Giraudeau B, Dibao-Dina C. Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study. *BMJ Open* 2024;**14**:e077582. doi:10.1136/bmjopen-2023-077582

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-077582>).

BG and CD-D contributed equally.

Received 11 July 2023

Accepted 07 February 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹UMR INSERM 1246 - SPHERE, University of Tours, Tours, Centre-Val de Loire, France

²INSERM CIC 1415, Tours University Hospital, Tours, France

³Department of general practice, University of Tours, Tours, France

Correspondence to

Dr Amandine Dugard;
amandinedugard@gmail.com

ABSTRACT

Objectives To compare the characteristics of patients with type 2 diabetes mellitus in general practice and those included in randomised controlled trials on which clinical practice guidelines are based.

Design Cross-sectional comparative study.

Setting We asked 45 general practitioners from three French Departments to identify the 15 patients with type 2 diabetes mellitus they most recently saw in consultation. In parallel, we selected randomised controlled trials included in the Cochrane systematic review on which the clinical practice guidelines for type 2 diabetes mellitus were based.

Participants We included 675 patients with type 2 diabetes mellitus, and data were collected from 23 randomised controlled trials, corresponding to 36 059 patients.

Outcome measures Characteristics of general-practice patients were extracted from medical records by a unique observer. The same baseline characteristics of patients included in randomised controlled trials from the Cochrane systematic review were extracted and meta-analysed. We assessed standardised differences between these two series of baseline characteristics. A difference greater than 0.10 in absolute value was considered meaningful.

Results General-practice patients were older than randomised controlled trial patients (mean (SD) 68.8 (1.1) vs 59.9 years (standardised difference 0.8)) and had a higher body mass index (mean (SD) 31.5 (6.9) vs 28.2 kg/m² (standardised difference 0.5)) but smoked less (11.0% vs 29.3% (standardised difference -0.6)). They more frequently used antihypertensive drugs (82.1% vs 37.5% (standardised difference 1.2)) but less frequently had a myocardial infarction (7.6% vs 23.1% (standardised difference -1.1)).

Conclusions Patients with type 2 diabetes mellitus cared for in general practice differ in a number of important aspects from patients included in randomised controlled trials on which clinical practice guidelines are based. This situation hampers the applicability of these guidelines. Future randomised trials should include patients who better fit the 'average' general-practice patient with type 2 diabetes mellitus to help improve the translation of study findings in daily practice.

STRENGTH AND LIMITATIONS OF THIS STUDY

- ⇒ Selected randomised controlled trials were published between 1995 and 2012 and patient care has evolved since then; however, actual recommendations are still based on these trials.
- ⇒ Some data were missing in trial reports, notably for cardiovascular history and drugs, which could have led to some overestimation or underestimation of the associated standardised differences.
- ⇒ We considered baseline characteristics of patients actually included in randomised controlled trials rather than selection criteria, which enabled us to estimate standardised differences.
- ⇒ General practitioners were from various areas and work organisations, and patients were randomly selected, which ensured generalisability of our results and limitation of bias."

INTRODUCTION

General practitioners are reluctant to apply the results of clinical trials to their patients.¹ One of the main reasons is the lack of representativeness of patients included in these trials.² In 2007, two studies, one of patients with asthma and the other of patients with hypertension, showed that a very small proportion of patients from general practice met the selection criteria of the randomised trials.^{3,4} More recently, in 2019, a third study showed the same kind of results for patients with type 2 diabetes mellitus.⁵ Indeed, older patients or those with multimorbidities are frequently excluded from such trials.⁶ However, primary care patients are frequently multimorbid.⁷ They also have less severe disease and more undifferentiated symptoms than patients included in randomised controlled trials.⁸

A common characteristic of the three studies is that they focused on the eligibility criteria of patients included in randomised controlled trials rather than

the characteristics of patients actually included in these trials. The trials were also conducted 10–15 years ago, but the report of the hypertensive study acknowledged that “[m]ore recent trials showed participants’ profiles that better reflected those of the patients under treatment in a general practice”.⁴ Therefore, the representativeness question should be re-investigated, as well because the generalisability of systematic reviews, which are based on randomised controlled trials, to primary care patients is rarely discussed.⁹

Type 2 diabetes mellitus is one of the most common conditions managed in primary care. The latest clinical practice guidelines for the treatment strategy for glycaemic control in type 2 diabetes mellitus are mainly based on the 2013 Hemmingsen *et al* review.¹⁰ Therefore, we selected type 2 diabetes mellitus as an illustrating disease to assess how primary care patients may differ from patients included in the randomised controlled trials on which the associated clinical practice guidelines are based.

METHODS

Study design and information sources

The present study was a comparative study. We used a sample of patients with type 2 diabetes mellitus that were included in a cross-sectional study in which general practitioners were invited to identify eligible patients. We also used theoretical values for patient characteristics derived from the Hemmingsen *et al* Cochrane review.¹⁰

Selection of general practitioners and patients

Eligible general practitioners were voluntary physicians practising on the date of the study from two different departments in France. We contacted by email eligible general practitioners who were practising as training supervisors from three different departments in France. These departments were selected for their diversity of practice area (rural or urban) and work organisation (only general practitioners, multidisciplinary health clinic, working alone). The patient study population consisted of adults aged 18 years or older with a diagnosis of type 2 diabetes mellitus in their medical records. We selected the last 15 eligible patients seen in consultation by each general practitioner. Information posted in the general practitioner’s waiting room was available for patients. We excluded patients who refused the use of their medical data had to tell their general practitioner and patients under 18 years of age.

Selection of the studies from the Cochrane review

Studies were eligible if they were randomised controlled trials included in the most recent Cochrane systematic review published in 2013 by Hemmingsen *et al*.¹⁰ We excluded reports of non-randomised trials, randomised controlled trials not written in English or reports of trials that did not describe patient baseline characteristics.

Data collection

We extracted data related to general practitioners, general-practice patients and randomised controlled trial patients by using three standardised spreadsheets that were developed and tested by the three authors.

General practitioner characteristics

For each general practitioner, we collected information on sex, age, distance from the hospital, practice area (rural, semi-rural, urban) and work organisation (multidisciplinary healthcare clinic, only physicians, working alone, other).

General-practice patient characteristics

From February to May 2022, data were collected from individual medical records by using a data extraction form. Prior to the visit, general practitioners had been asked to identify the 15 eligible patients with type 2 diabetes mellitus most recently seen. The following variables were collected: sex, age, cardiovascular risk factors (smoking status, weight and body mass index (BMI), serum cholesterol and triglycerides levels, blood pressure), diabetes duration, glycosylated haemoglobin level, serum creatinine level, cardiovascular history, glucose-lowering medications (oral glucose-lowering drug and insulin) and cardiovascular medications (antihypertensive drugs, lipid-lowering drugs and aspirin).

Randomised controlled trial patient characteristics

From trial reports, one of us (AD) collected selection criteria and patient baseline characteristics. The collected variables were the same as those collected for general-practice patients.

Statistical analysis

No sample size calculation was performed because no quantitative hypothesis was formulated. However, we asked each general practitioner to identify 15 patients and initially expected to have 50 general practitioners agreeing to participate in the study.

For general-practice patients, continuous data extracted from the medical fields are expressed as mean (SD) and binary variables as numbers (percentage). For patients included in randomised controlled trials, we performed a random meta-analysis for each baseline characteristic to assess a mean value (online supplemental appendix 1). This value was then considered a theoretical one to which summary statistics estimated from the sample of primary care patient baseline characteristics were compared. Hence, we assessed standardised differences, with a standardised difference of >0.10 (meaning a difference in means of more than 0.1 SD) denoting a meaningful difference.

Patients and public involvement

None.

RESULTS

Characteristics of the general practitioners

Of the 71 general practitioners contacted by email, 45 agreed to participate and included 675 patients. One

Table 1 Characteristics of the general practitioners (n=45)

Age (years), mean (SD)	42.1 (8.0)
Female sex	19 (42.2)
Distance from hospital (km), mean (SD)	12.8 (10.3)
Location of the practice	
Urban	13 (28.9)
Rural	15 (33.3)
Semi-rural	17 (37.8)
Work organisation	
Multidisciplinary healthcare clinic	26 (57.8)
Only physicians	17 (37.8)
Working alone	1 (2.2)
Municipal health centre	1 (2.2)

Data are n (%) unless otherwise indicated.

general practitioner refused to participate and 25 others did not answer. The mean (SD) age was 42.1 (8.0) years, and more than half of the general practitioners worked in a multidisciplinary clinic (table 1).

Selection of the randomised controlled trials

Among the 28 trials included in the Cochrane systematic review, 23 were selected for this study, corresponding to 36 059 patients. Two reports were unavailable, one was written in Russian and another in Chinese, and the last one reported no patient baseline characteristics. References and characteristics of the 23 trials are in online supplemental appendices 2 and 3, table 1.

Comparison of baseline characteristics of primary care patients and patients included in randomised controlled trials

General-practice patients were older than randomised controlled trial patients (mean (SD) 68.8 (11.1) vs 59.9 years (standardised difference 0.8)), they had higher mean BMI (31.5 (6.9) kg/m² vs 28.2 kg/m² (standardised difference 0.5)) but smoked less (11.0% vs 29.3% (standardised difference -0.6)). They also had less history of myocardial infarction (7.6% vs 23.1% (standardised difference -1.1)). General-practice patients more frequently took oral hypoglycaemic drugs (82.1% vs 37.5% (standardised difference 1.2)) and anti-hypertensive drugs (82.1% vs 37.5% (standardised difference 1.2)) than randomised controlled trial patients (figure 1).




Figure 1 Comparison of the characteristics of general practice patients and randomised trials patients (legends). Each subfigure displays the comparison of general practice patients to patients included in randomised trials. For the former, summary statistics (means and SD, or percentages) are reported on the right; for the former, a mean value (considered as a theoretical value) was obtained through meta-analyses of baseline characteristics of the patients included in the selected randomised trials. For each characteristic, a standardised difference between general practice and randomised patients was estimated and plotted. The dotted lines in -0.1 and 0.1 SD define the limits of a non-meaningful standardised difference. ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; BP, blood pressure; Hba1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.



DISCUSSION

We found substantial differences in characteristics between general-practice type 2 diabetes mellitus patients and those included in the randomised controlled trials on which the associated clinical guidelines are based. General-practice patients were older, had higher BMI, more frequently took anti-hypertensive and lipid-lowering drugs but had less cardiovascular history than randomised controlled trial patients.

A strength of this study is that it considered baseline characteristics of patients actually included in randomised controlled trials rather than selection criteria. Doing so allowed us to estimate standardised differences, revealed to be very high for some variables, thus illustrating huge discrepancies between general-practice patients and patients included in randomised controlled trials. Another strength is that the general practitioners selected for this study were from various areas and work organisations, which ensured good generalisability of our results. Finally, we collected data from the last 15 patients seen in consultation with the general practitioner, thus leading to a randomly selected sample, which limits bias. However, the study has some limitations. First, the Hemmingsen *et al* review was published in 2013 and the randomised controlled trials included were published between 1995 and 2012. Also, patient care may have evolved. For example, cardiovascular risk in patients with type 2 diabetes mellitus has decreased with the use of angiotensin-converting enzyme inhibitors¹¹ and the introduction of statins.¹² This approach could explain why general-practice patients seen in consultation in 2022 were more likely to use angiotensin-converting enzyme inhibitors or lipid-lowering medications than participants of the randomised controlled trials. However, recommendations for control of glycosylated haemoglobin levels in patients with type 2 diabetes mellitus are still based on the results of these trials and to our knowledge, there has been no recent randomised trial. Furthermore, more recent studies of diabetes mellitus, especially testing new antidiabetic therapies, also found a low representativeness of patients included in the trials (in contrast to our study, they focused on eligibility criteria rather than inclusion characteristics).^{5 13} Second, our sample of general practitioners was a convenience sample rather than a random sample of general practitioners, as were the patients included in the study because we chose people who agreed to participate. This study population could be quite different from the ‘general population’ in terms of sociodemographic and other factors. A solution may have been to use population data sets or representative samples often taken from electronic health records as a control group; however, people in population data sets may not necessarily consult their general practitioner and therefore may not be representative of the patients consulting a general practitioner, as shown in the ecology of medical care by Green *et al*.¹⁴ Finally, some data were missing in trial reports, notably for cardiovascular history and drugs, which could have led to some overestimation

or underestimation of the associated standardised differences. However, except for a history of angina, hypertension and stroke, mean values derived from meta-analyses of baseline patient characteristics of randomised controlled trials were based on more than 15 000 patients.

Conclusions

Randomised controlled trials of type 2 diabetes mellitus on which recommendations are based included participants that were not fully representative of general-practice patients. There is a need for studies including a wider range of patients with type 2 diabetes mellitus such as older patients or those with polypharmacy to ensure a better generalisability of the results.

Contributors AD, CD-D and BG conceived the study. AD participated in data collection. AD extracted the data. BG and AD analysed data. AD wrote the first draft of the manuscript, which was revised by CD-D and BG. All coauthors read and approved the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The Ethics Committee of the CHRU of Tours approved the study protocol (no. 2022_005, dated 24 March 2022). The French committee for data handling (CNIL) approved the study (no. 2022_006, dated 27 January 2022). Information posted in the general practitioner’s waiting room was available for patients.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. De-identified participant data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Amandine Dugard <http://orcid.org/0000-0001-7384-5459>

Clarisse Dibao-Dina <http://orcid.org/0000-0002-1750-2846>

REFERENCES

- 1 Fahey T. Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future. *Br J Gen Pract J R Coll Gen Pract* 1998;48:1173–8.
- 2 Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply” *The Lancet* 2005;365:82–93.
- 3 Travers J, Marsh S, Williams M, *et al*. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply *Thorax* 2007;62:219–23.

- 4 Uijen AA, Bakx JC, Mokkink HGA, *et al.* Hypertension patients participating in trials differ in many aspects from patients treated in general practices. *J Clin Epidemiol* 2007;60:330–5.
- 5 Canivell S, Mata-Cases M, Vlachos B, *et al.* How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? estimations from a population database in a Mediterranean area. *J Diabetes Res* 2019;2019:2018374.
- 6 Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. *BMJ* 1997;315:1059.
- 7 Barnett K, Mercer SW, Norbury M, *et al.* Epidemiology of Multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *The Lancet* 2012;380:37–43.
- 8 Sonis J. Applicability of clinical trial results to primary care. *JAMA* 1998;280:1746–a.
- 9 Missiou A, Tatsioni A. Systematic reviews do not comment on applicability for primary care. *J Clin Epidemiol* 2015;68:1152–60.
- 10 Hemmingsen B, Lund SS, Gluud C, *et al.* Targeting intensive Glycaemic control versus targeting conventional Glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2013.:CD008143.
- 11 Effects of Ramipril on cardiovascular and Microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE Substudy. *Lancet* 2000;355:253–9.
- 12 Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of Statins: a meta-analysis. *Lancet* 2008;371:117–25.
- 13 Sen A, Goldstein A, Chakrabarti S, *et al.* The Representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0. *J Am Med Inform Assoc* 2018;25:239–47.
- 14 Green LA, Fryer GE, Yawn BP, *et al.* The Ecology of medical care Revisited. *N Engl J Med* 2001;344:2021–5.